<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02359838</url>
  </required_header>
  <id_info>
    <org_study_id>14-515</org_study_id>
    <nct_id>NCT02359838</nct_id>
  </id_info>
  <brief_title>Patient-Centered Care for the Older Adult With Hematologic Malignancy</brief_title>
  <official_title>Patient-Centered Care for the Older Adult With Hematologic Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is evaluating if co-management by a geriatrician embedded in the oncology&#xD;
      clinic can improve outcomes for frail older adults with blood cancers. A rigorous pre-entry&#xD;
      frailty assessment by a trained research assistant will be followed by randomization to&#xD;
      geriatrician co-management versus usual care for patients found to be frail or pre-frail.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Older adults have unique health concerns, and in particular, older adults with blood cancers&#xD;
      may have different disease and other health related issues than younger adults with similar&#xD;
      diagnoses. One aspect of aging which can make older adults more vulnerable is frailty.&#xD;
      Frailty is a general term that describes a decline in multiple areas of health, including the&#xD;
      loss of energy, physical ability, and mental ability. Frailty can make it difficult for&#xD;
      patients with cancer to respond to treatment and more likely to have side effects. On the&#xD;
      other hand, many older patients are not frail despite advanced age. This study is being done&#xD;
      to determine if co-management by a geriatrician of older adults who are found to be frail&#xD;
      through a detailed baseline assessment can improve outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>One year</time_frame>
    <description>Overall Survival at one year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalizations</measure>
    <time_frame>6 months</time_frame>
    <description>Number of Hospitalizations 6 months after enrollment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Frail/pre-frail hematologic oncology patients receive usual care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Geriatrician Co-Management</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Frail/pre-frail hematologic oncology patients receive co-management by a geriatrician</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Baseline Geriatric Screening/Assessment</intervention_name>
    <description>All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.</description>
    <arm_group_label>Geriatrician Co-Management</arm_group_label>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Geriatrician Co-Management</intervention_name>
    <description>A board-certified geriatrician embedded in the oncology clinic will co-manage patients randomized to this arm.</description>
    <arm_group_label>Geriatrician Co-Management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients aged 75 and older who present for an initial consultation at the&#xD;
             Dana-Farber/Brigham and Women's Cancer Center for hematologic malignancy&#xD;
             (transplantation consultation excluded).&#xD;
&#xD;
          -  Assessed to be pre-frail or frail on formal baseline geriatric assessment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not willing to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory A. Abel, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana Faber Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jane A Driver, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 2, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2015</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Gregory A. Abel, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hematologic Malignancy</keyword>
  <keyword>Geriatric Assessment</keyword>
  <keyword>Geriatric Oncology</keyword>
  <keyword>Frailty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

